Core Viewpoint - MDB Capital Holdings is making significant progress in scaling its public venture platform and aims to create a diversified portfolio of high-potential public venture opportunities [3]. Operational Highlights - The company anticipates closing two offerings shortly: a $16.8 million private placement for Paulex Bio, focused on diabetes therapeutics, and a $20 million IPO for Buda Juice, which offers UltraFresh™ cold-crafted juices [8]. - MDB Capital has expanded its pipeline of early-stage, disruptive companies that have the potential to lead in new categories [8]. - The firm is improving the efficiency of its public venture platform to better identify and prepare new category-leading companies with disruptive technologies [8]. - MDB welcomed TCA Venture Group and Keiretsu Forum MST angel group investors into its latest offerings, enhancing its investor community [8]. - The company has broadened relationships with Registered Investment Advisors (RIAs) to attract new investors seeking alternative investment strategies [8].
MDB Capital Holdings Provides Third Quarter 2025 Update